Neurodegenerative Disease Therapeutics Industry | Forecast 2030

Neurodegenerative Disease Therapeutics Industry Data Book - Parkinson’s Disease Treatment and Alzheimer's Therapeutics Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 – 2030

The global neurodegenerative disease markets combine to account for USD 8.33 billion revenue in 2021, which is expected to reach USD 28.15 billion by 2030, growing at a cumulative rate of 15.6% over the forecast period. 

Access the Global Neurodegenerative Disease Therapeutics Industry Data Book, 2022 to 2030, compiled with details like market sizing forecasts insights, regulatory technology framework, pricing intelligence, competitive benchmarking analyses, macro-environmental analyses studies.

Parkinson’s Disease Treatment Market Growth Trends

The global Parkinson’s disease treatment market size is expected to reach USD 11.98 billion by 2030, according to a new report by Grand View Research, Inc., growing at a CAGR of 12.1% from 2022 to 2030. This can be attributed to the rising investment in the research and development of novel treatments for PD. In August 2021, the Parkinson’s Foundation announced an investment of USD 43 million as a research grant to 29 research projects having the goal of developing novel treatments and therapies for PD. In addition, in May 2021, the Parkinson’s Foundation announced an investment of USD 10 million for research, care, and educational programs related to Parkinson’s Disease (PD). This investment may aid in providing awareness and genetic testing free of cost to people suffering from PD.

Such investment initiatives are expected to boost industry growth. In the last ten years, there have been significant RD activities in the PD therapy sector, leading to the development of innovative drug-delivery methods. Due to fewer side effects, these cutting-edge drug delivery systems outperform the existing ones. In addition, the rate of prescription for these techniques has increased due to a rise in patient compliance, which is fueling the expansion of the industry. Moreover, key pharmaceutical companies are undertaking initiatives, such as collaborations and partnerships, for the development, manufacturing commercialization of products to meet the rising demand for disease treatment in the international market.

For instance, in November 2021, STADA Arzneimittel and Bioglan formed a partnership to expand the production capacity of the medicine Lecigon (levodopa/carbidopa/entacapone) used to treat patients with PD. Thus, increasing demand for medicines that are used to treat patients with PD is anticipated to drive industry growth. However, the limited availability of neurologists leads to issues, such as longer waiting times for patients and difficulty in hiring new neurosurgeons in hospitals. In addition, some of the currently practicing neurologists avoid accepting new Medicaid patients, which creates difficulty for patients who want to switch to another doctor. According to the American Academy of Neurology (AAN) report, around 19% shortage of neurologists is projected by 2025.

Order your copy of the Free Sample of “Neurodegenerative Disease Therapeutics Industry Data Book - Parkinson’s Disease Treatment and Alzheimer's Therapeutics Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

Alzheimer’s Therapeutics Market Growth Trends 

The global Alzheimer’s therapeutics market size is expected to reach USD 15.6 billion by 2030, according to a new study by Grand View Research Inc. It is expected to expand at a CAGR of 16.2% from 2022 to 2030. Government organizations are engaged in providing funds for Alzheimer's support, care, and research activities, which is projected to fuel the market growth. For instance, in March 2022, the Alzheimer's Society announced to spend around USD 3.5 billion in the coming years on dementia research to improve the care of patients.

Additionally, the Alzheimer's Association with the Alzheimer's Impact Movement (AIM) announced to utilize USD 25 million to implement the BOLD Infrastructure for Alzheimer's Act to create an effective public health substructure for patients. In addition, in September 2021, the South Texas Alzheimer's Disease Center and the Duke/University of North Carolina Alzheimer's Disease Research Center were granted USD 14.8 million over five years by the National Institute of Aging to encourage research on risk factors related to AD. 

Furthermore, an increase in the incidence and cost burden of dementia associated with AD is expected to boost the market growth. According to the Alzheimer's Society, around 900,000 people are living with dementia in the United Kingdom, and it is projected to rise to 1.6 million by 2040 and the incidence of dementia will be 209,600 in the same year. 

The current standard of care is limited to symptom-relieving drugs. Therefore, the approval of disease-modifying anti-amyloid therapeutics is expected to change the treatment landscape. For instance, in June 2021, the U.S. FDA granted accelerated approval to Aduhelm (aducanumab) for the treatment of patients with Alzheimer’s disease. It is a monoclonal antibody that targets cluster forms of amyloid beta present in the brains of patients and stops its formation. Other key anti-amyloid monoclonal antibodies in late-stage clinical trials include Gantenerumab (F. Hoffmann-La Roche Ltd.), Solanezumab (Eli Lilly and Company), and Lecanemab (Eisai Inc./Biogen), among others.  

Competitive Landscape

Key players operating in the neurodegenerative disease therapeutics industry are -

• Cerevel Therapeutics
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Merck Co., Inc.
• GlaxoSmithKline plc. (GSK)
• AbbVie, Inc.
• Supernus Pharmaceuticals, Inc.
• Eisai Co., Ltd.
• Adamas Pharmaceuticals, Inc.
• Biogen
• AC Immune
• DAIICHI SANKYO COMPANY, LIMITED
• Johnson Johnson Services Inc.
• TauRx Pharmaceuticals Ltd.
• Hoffmann La Roche Ltd.

Grand View Research’s Neurodegenerative Disease Therapeutics Industry data book is a collection of market sizing information forecasts, regulatory data, reimbursement structure, competitive benchmarking analyses, macro-environmental analyses, and regulatory technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research.

Check out more Industry Data Books, published by Grand View Research 

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.